You are here
P&T August 2014
A comprehensive analysis of malpractice claims experience from a professional liability insurer, Healthcare Providers Service Organization, can help P&T committees better understand the risks and challenges they encounter each day.
Irritable bowel syndrome, a functional gastrointestinal disorder of uncertain pathophysiology, affects up to 55 million Americans. Medications available or in development include antispasmodics, antidepressants, and antidiarrheals.
As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn’s disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
FDA approvals, drug indications, and updates
Vedolizumab (Entyvio) for ulcerative colitis and Crohn’s disease; dalbavancin (Dalvance) for acute bacterial skin and skin structure infections; and antihemophilic factor, recombinant (Eloctate) for hemophilia A
Tedizolid phosphate: a second-generation oxazolidinone for acute bacterial skin and skin structure infections
Attendees at the 19th Congress of the European Hematology Association in Milan, Italy, heard reports on new therapies for acute myeloid leukemia, chronic lymphocytic leukemia, β-thalassemia, multiple myeloma, and polycythemia vera.